Lymphoma, B-Cell

• 

  Subject Areas on Research

  • A c-Myc and surface CD19 signaling amplification loop promotes B cell lymphoma development and progression in mice. 
  • A complex role for Bcl10 in kidney injury. 
  • A glycoengineered anti-CD19 antibody with potent antibody-dependent cellular cytotoxicity activity in vitro and lymphoma growth inhibition in vivo. 
  • A loss-of-function RNA interference screen for molecular targets in cancer. 
  • A new model of Epstein-Barr virus infection reveals an important role for early lytic viral protein expression in the development of lymphomas. 
  • A phase III study of anti-B4-blocked ricin as adjuvant therapy post-autologous bone marrow transplant: CALGB 9254. 
  • A role for E2F activities in determining the fate of Myc-induced lymphomagenesis. 
  • A sinusoidal large cell lymphoma with expression of CD30, CD15, and multiple B-cell antigens: a classical Hodgkin lymphoma with sinusoidal infiltrating pattern or a sinusoidal CD30 positive large B-cell lymphoma with CD15? 
  • A systems biology view of cancer. 
  • Aberrant immunoglobulin class switch recombination and switch translocations in activated B cell-like diffuse large B cell lymphoma. 
  • Adoptive transfer of cytotoxic T lymphocytes for the treatment of transplant-associated lymphoma. 
  • Adult high-grade B-cell lymphoma with Burkitt lymphoma signature: genomic features and potential therapeutic targets. 
  • An oncogenic Ezh2 mutation induces tumors through global redistribution of histone 3 lysine 27 trimethylation. 
  • Anti-CD37 chimeric antigen receptor T cells are active against B- and T-cell lymphomas. 
  • Association of methotrexate, rheumatoid arthritis and lymphoma: report of 2 cases and literature review. 
  • Associations between genome-wide Native American ancestry, known risk alleles and B-cell ALL risk in Hispanic children. 
  • B cells in epithelial and perivascular compartments of human adult thymus. 
  • B-cell lymphoma with hyaline vascular Castleman disease-like features: a clinicopathologic study. 
  • BCL2 translocation defines a unique tumor subset within the germinal center B-cell-like diffuse large B-cell lymphoma. 
  • Biliary stricture secondary to donor B-cell lymphoma after orthotopic liver transplantation. 
  • Biomimetic, synthetic HDL nanostructures for lymphoma. 
  • Brief report: lymphoma of donor origin occurring in the porta hepatis of a transplanted liver. 
  • CD3-positive plasmablastic B-cell neoplasms: a diagnostic pitfall. 
  • CLL-137 SEQUOIA: Results of a Phase 3 Randomized Study of Zanubrutinib Versus Bendamustine + Rituximab (BR) in Patients With Treatment-Naïve (TN) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/ SLL). 
  • Chromosomal abnormalities and molecular genetics of non-Hodgkin's lymphoma. 
  • Chronic Lymphocytic Leukemia With Two B-Cell Populations of Discordant Light Chain Restrictions in Individual Patients: Parallel Development of Biclonal B-Cell Neoplasms or Clonal Evolution With Isotype Switch? 
  • Coincident Merkel cell carcinoma and B-cell lymphoma: a report of two cases evaluated by cytology. 
  • Composite lymphoid neoplasm of B-cell and T-cell origins: a pathologic study of 14 cases. 
  • Composite lymphoma of follicular B-cell and peripheral T-cell types with distinct zone distribution in a 75-year-old male patient: a case study. 
  • Composite lymphoma of mycosis fungoides and cutaneous small B-cell lymphoma in a 73-year-old male patient. 
  • Comprehensive analysis of the gene expression profiles in human gastric cancer cell lines. 
  • Concomitant Waldenstrom macroglobulinemia and IgA plasmablastic myeloma in a patient with untreated IgM paraproteinemia: sequential development of biclonal B-cell neoplasms over a 10-year period in a single individual. 
  • Contribution of F-18 FDG PET-CT in the detection of systemic spread of primary central nervous system lymphoma. 
  • Crystal-storing histiocytosis: a clinicopathological study of 13 cases. 
  • Cutaneous Lymphoma. 
  • Cutaneous granulomas in children with combined immunodeficiency. 
  • Detection of Epstein-Barr virus in transformations of low-grade B-cell lymphomas after fludarabine treatment. 
  • Diagnostic impact of core-needle biopsy on fine-needle aspiration of non-Hodgkin lymphoma. 
  • Differential phosphorylation of functional tyrosines in CD19 modulates B-lymphocyte activation. 
  • Diffuse intraabdominal lymphoma complicating idiopathic myelofibrosis: CT demonstration. 
  • Do germinal centers have a role in the generation of lymphomas? 
  • Dysregulation of fatty acid synthesis and glycolysis in non-Hodgkin lymphoma. 
  • EBV⁺ high-grade B cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements: a multi-institutional study. 
  • Effects of cyclosporine on human B-cell lymphoma development in vivo. 
  • Epstein-Barr virus-associated lymphoproliferative disorder following autologous bone marrow transplantation for non-Hodgkin's lymphoma. 
  • Evaluation, Diagnosis, and Staging of Cutaneous Lymphoma. 
  • Expanding anti-CD38 immunotherapy for lymphoid malignancies. 
  • Flow cytometric analysis of immunoglobulin heavy chain expression in B-cell lymphoma and reactive lymphoid hyperplasia. 
  • GNA13 loss in germinal center B cells leads to impaired apoptosis and promotes lymphoma in vivo. 
  • Galectin-1 drives lymphoma CD20 immunotherapy resistance: validation of a preclinical system to identify resistance mechanisms. 
  • Gene expression signatures and outcome prediction in mature B-cell malignancies. 
  • Gene profiling of canine B-cell lymphoma reveals germinal center and postgerminal center subtypes with different survival times, modeling human DLBCL. 
  • Genotypic divergence precedes clinical dissemination in a case of synchronous bilateral B-cell malignant lymphoma of the testes. 
  • Gradient lasso for Cox proportional hazards model. 
  • High-grade B cell lymphoma, unclassifiable, with blastoid features: an unusual morphological subgroup associated frequently with BCL2 and/or MYC gene rearrangements and a poor prognosis. 
  • Histiocytic sarcoma arising in indolent small B-cell lymphoma: report of two cases with molecular/genetic evidence suggestive of a 'transdifferentiation' during the clonal evolution. 
  • Human B-cell lymphoma in severe combined immunodeficient mice after active infection with Epstein-Barr virus. 
  • Imbalanced matriptase pericellular proteolysis contributes to the pathogenesis of malignant B-cell lymphomas. 
  • Immunotherapy of B-cell malignancies with genetically engineered human CD8+ natural killer T cells. 
  • In vitro and in vivo activity of murine lymphokine-activated killer cells after cryopreservation. 
  • In vivo expansion, persistence, and function of peptide vaccine-induced CD8 T cells occur independently of CD4 T cells. 
  • Large-cell lymphoma presenting with a distinctive inflammatory dermatosis. 
  • Lymphoma depletion during CD20 immunotherapy in mice is mediated by macrophage FcgammaRI, FcgammaRIII, and FcgammaRIV. 
  • MYC-driven aggressive B-cell lymphomas: biology, entity, differential diagnosis and clinical management. 
  • MYC/BCL2 double-hit high-grade B-cell lymphoma. 
  • Maintenance of long-lived plasma cells and serological memory despite mature and memory B cell depletion during CD20 immunotherapy in mice. 
  • Managing Patients with Cutaneous B-Cell and T-Cell Lymphomas Other Than Mycosis Fungoides. 
  • Mantle cell lymphoma with plasma cell differentiation. 
  • Membranoproliferative glomerulonephritis type I, mixed cryoglobulinemia and lymphoma in the absence of hepatitis C infection. 
  • Metachronous/concomitant B-cell neoplasms with discordant light-chain or heavy-chain isotype restrictions: evidence of distinct B-cell neoplasms rather than clonal evolutions. 
  • Molecular diagnosis of Burkitt's lymphoma. 
  • NCCN Guidelines® Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 3.2022. 
  • Non-Hodgkin Lymphomas: Malignancies Arising from Mature B Cells. 
  • Non-Hodgkin lymphoma presenting with obstructive jaundice. 
  • PD-1 expression and clinical PD-1 blockade in B-cell lymphomas. 
  • Pediatric primary bone lymphoma-diffuse large B-cell lymphoma: morphologic and immunohistochemical characteristics of 10 cases. 
  • Peripheral eosinophil counts predict efficacy of anti-CD19 CAR-T cell therapy against B-lineage non-Hodgkin lymphoma. 
  • Phase I Study of the Combination of Bendamustine, Rituximab, and Pixantrone in Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma. 
  • Phase I Study of the Investigational Aurora A Kinase Inhibitor Alisertib plus Rituximab or Rituximab/Vincristine in Relapsed/Refractory Aggressive B-cell Lymphoma. 
  • Phase I studies of interleukin (IL)-2 and rituximab in B-cell non-hodgkin's lymphoma: IL-2 mediated natural killer cell expansion correlations with clinical response. 
  • Pilot study of modified LMB-based therapy for children with ataxia-telangiectasia and advanced stage high grade mature B-cell malignancies. 
  • Plasmacellular differentiation in extranodal marginal zone B cell lymphomas of the ocular adnexa: an analysis of the neoplastic plasma cell phenotype and its prognostic significance in 136 cases. 
  • Posttransplant lymphoproliferative disorder following nonmyeloablative allogeneic stem cell transplantation. 
  • Primary central nervous system lymphoma with systemic metastasis: case report and review. 
  • Primary central nervous system lymphoma, presenting as diabetes insipidus, as a sequela of hepatitis C. 
  • Primary central nervous system posttransplant lymphoproliferative disorders. 
  • Primary intraocular T-cell-rich large B-cell lymphoma. 
  • Reduced-intensity allogeneic transplantation provides high event-free and overall survival in patients with advanced indolent B cell malignancies: CALGB 109901. 
  • Rituximab in lymphocyte predominance Hodgkin's disease: a case series. 
  • SWOG 1318: A Phase II Trial of Blinatumomab Followed by POMP Maintenance in Older Patients With Newly Diagnosed Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia. 
  • Salivary gland lesions with a prominent lymphoid component: cytologic findings and differential diagnosis by fine-needle aspiration biopsy. 
  • Sequential high-dose ifosfamide, carboplatin and etoposide with rituximab for relapsed Hodgkin and large B-cell non-Hodgkin lymphoma: increased toxicity without improvement in progression-free survival. 
  • Stem cell factor expression in B cell malignancies is influenced by the niche. 
  • Systemic interleukin-2 and adoptive transfer of lymphokine-activated killer cells improves antibody-dependent cellular cytotoxicity in patients with relapsed B-cell lymphoma treated with rituximab. 
  • T helper 2-dominant antilymphoma immune response is associated with fatal outcome. 
  • TET2 Deficiency Sets the Stage for B-cell Lymphoma. 
  • The Tumor Microenvironment Regulates CD19 and CD20 Immunotherapy for Lymphoma. 
  • The biology of human lymphoid malignancies revealed by gene expression profiling. 
  • The role of microRNAs in Epstein-Barr virus latency and lytic reactivation. 
  • The value of fluorescence in situ hybridization and polymerase chain reaction in the diagnosis of B-cell non-Hodgkin lymphoma by fine-needle aspiration. 
  • Transformation of follicular lymphoma to precursor B-cell lymphoblastic lymphoma with c-myc gene rearrangement as a critical event. 
  • Triple-hit B-cell Lymphoma With MYC, BCL2, and BCL6 Translocations/Rearrangements: Clinicopathologic Features of 11 Cases. 
  • Tumor interferon signaling and suppressive myeloid cells are associated with CAR T-cell failure in large B-cell lymphoma. 
  • U19/Eaf2 knockout causes lung adenocarcinoma, B-cell lymphoma, hepatocellular carcinoma and prostatic intraepithelial neoplasia. 
  • Uncovering the Role of RNA-Binding Protein hnRNP K in B-Cell Lymphomas. 
  • Utilization of pathway signatures to reveal distinct types of B lymphoma in the Emicro-myc model and human diffuse large B-cell lymphoma. 
  • Utilization of the Eμ-Myc mouse to model heterogeneity of therapeutic response. 
  • Venous thromboembolism in patients with diffuse large B-cell lymphoma. 
  • Virally induced cellular microRNA miR-155 plays a key role in B-cell immortalization by Epstein-Barr virus. 
• 

  Keywords of People

  • Allen, Nancy Bates, Professor Emeritus of Medicine, Medicine, Rheumatology and Immunology
  • Lagoo, Anand Shreeram, Professor of Pathology, Pathology
  • Luftig, Micah Alan, Professor of Molecular Genetics and Microbiology, Cell Biology
  • Rodgers, Thomas, Assistant Professor of Medicine, Duke Cancer Institute
  • Stefanovic, Alexandra, Associate Professor of Medicine, Medicine, Hematologic Malignancies and Cellular Therapy